Immune mechanisms in vitiligo

Clinics in Dermatology

Volumn 15, Issue 6, 1997, Pages 853-861

  Bystryn, Jean Claude ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CATALASE; CATECHOLAMINE; FREE RADICAL; HLA ANTIGEN; HYDROGEN PEROXIDE; INTERCELLULAR ADHESION MOLECULE 1; MELANIN; MEMBRANE ANTIGEN; MONOPHENOL MONOOXYGENASE; TETRAHYDROBIOPTERIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNITY; CATECHOLAMINE SYNTHESIS; CELLULAR IMMUNITY; ETIOLOGY; HUMAN; KERATINOCYTE; LANGERHANS CELL; MELANOCYTE; MELANOGENESIS; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VITILIGO;

EID: 0030727763     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00126-0     Document Type: Article

References (89)

1. Klaus S. Lerner AB. Vitiligo. J Am Acad Dermatol 1984; 11:997-1000.
2. Smyth JR, Boissy RE, Fite KV. The DAM chicken: A model for spontaneous postnatal cutaneous and ocular amelanosis. J Hered 1981;72:150-56.
3. Mahaffey MD, Yarbrough KM, Munnell F. Focal loss of pigment in the Belgian Tervuren dog. J Am Vet Med Assoc 1978:173:390-96.
4. Lerner AB, Nordlund JJ. Vitiligo: The loss of pigment in skin, hair and eyes. J Dermatol 1978:5:1-8.
5. Lerner AB, Cage GW. Melanomas in horses. Yale J Biol Med 1973;46:646-50.
6. Millikan LE, Hook RR, Manning PJ, Gross and ultrastructural studies in a new melanoma model: The Sinclair swine. Yale J Biol Med 1973;46:631-45
7. Mosher DB, Fitzpatrick TB, Ortonne J, et ai. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, editors. Dermatology in general medicine. New York: McGrav/-Hill, !987;794876.
8. Metzker A, Zamir R, Gazit E, et ai. Virihgo and the HL.A system. Dermatologica 1980;160:10U-5,
9. Foley LM, Lowe N], Mishelhoff E, et al. Association ot HLA-DR4 with vitiligo. J Am Acad Oer-natol 1983:8:3940.
10. Das SK, Majumber PP, Majumber TK, ev al. Genet Epidemiol 1985;2:255-62.
11. Dunston GM, Halder RM. Vitiligo is associated with HLA-DR4 in black patients. Arch Dermaiol 1990; 126:5660.
12. Retornaz G, Betuel H, Ortonne JP, et al fl. A antigen and vitiligo. Br J Dermatol 1976;95:173-5.
13. Orecchia G, Perfetti L, Malagoli P, et ai. Vitiligo is associated with a significant increase in HLA-A30 Cvv6 and DQw3 and a decrease in C4AQO in northern Stalian patients. Dermatology 1992:185:123-27.
14. Lerner AB, Nordlund JJ. Vitiligo: What is it? k it important? JAMA 1978:239:1183-7.
15. Bhawan J, Bhutan! LK. Keratinocvte damage in vitiligo. J Cutan Pathol 1983;10:207-12.
16. Moellman G, Klein-Angerer S, Scolay DA, et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis ot patients with vitiligo. J Invest Dermatol 1982:79:321 - V.
17. Gokhale BB, Mehta LN. Histopatholoey ot vitiliginous skin. Int J Dermatol 1983:22:477-80.
18. Ortonne JP, Mosher DB, Fitzpatrick TB, editors. Vitiligo and other hypomelanoses of hair arid skin. New York: Plenum, 1983:129-30.
19. Naughton GK, Eisinger M, Bystryn i-C Antibodies to normal human melanocytes in vitiligo j Exp Med 1983; 158:246-51.
20. Mitchell MS, Nordlund JJ, Lerner AB, et ai. Comparison of cell-mediated immunity to melanoma cells m patients vvith vitiligo, halo nevi, or melanom.: Invest Dermatol 1980;75:144-47.
21. Bystryn J-C. Naughton GK. The significance of vitiligo antibodies. J Dermatol 1985;12:l-9.
22. I'awelek J, Korner A, Bergstrom A. New regulation of melanin biosynthesis and autodestruction of melanoma cells. Nature 1980;286:6l7-9.
23. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. I invest Derm 1991:97:1081-5.
24. Schallreuter KU, Wood JM, Ziegler ;, et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo Biochim Biophys Acta 1994:1226:181-92.
25. Schallreuter KU, Wood JM, Pittelkow MK, et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996;288:14-8.
26. Nordlund JJ, Lerner AB. Vitiligo. It is important. Arch Dermatol 1982;118:5-8.
27. Scholtz JR, Williamson C Jr. Vitiligo in dermatomal distribution. AMA Arch Dermat and Syph 1951;64:366-369.
28. Lerner A. Vitiligo. J Invest Derm 1959;32:285-310.
29. Ortonne JP, Mosher DB, Fitzpatrick TB, editors. Vitiligo and other hypomelanoses of hair and skin. New York: Plenum, 1983:257-8.
30. Norris DA, Capin L, Muglia JJ, et al. Enhanced susceptibility of melanocytes to different immunologie effector mechanisms in vitro: Potential mechanisms for postinflammatory hypopigmentation and vitiligo. Pigment Cell Res Suppl 1988;l:113-23.
31. Yu HS, Kao CH, Yu CL. Co-existence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993;100:823-8.
32. Wagoner MD, Albert DM, Lerner AB, et al. New observations on vitiligo and ocular disease. Am J Ophthalmol 1983;96:16-26.
33. Burns RP, Feeney-Burns L, Hook RR, et al. Depigmentation and blindness in malignant melanoma swine. ARVO Abstracts. Invest Ophthalmol Vis Sei 1980;19(Suppl): 127(7).
34. Smyth JR, Boissy RE, Fite KV, et al. Retinal dystrophy associated with a postnatal amelanosis in the chicken. Invest Ophthalmol Vis Sei 1981;20:799-803.
35. Parrish JA, Fitzpatrick TB, Shea C, et al. Photochemotherapy of vitiligo: Use of orally administered psoralens and a high intensity longwave ultraviolet light system. Arch Dermatol 1976;112:1531-4.
36. Kumari J. Vitiligo treated with topical clobestasol propionate. Arch Dermatol 1984;120:631-5.
37. Tsuji T, Hamada T. Topically administered fluoracil in vitiligo. Arch Dermatol 1983;119:722-7.
38. Cunliffe WJ, Hall R, Newell DJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968;80:135-9.
39. Brastoff J, Bor S, Feiwel M. Autoantibodies in patients with vitiligo. Lancet 1969;2:177-8.
40. Bor S, Feiwel M, Chanarain I. Vitiligo and its aetiological relationship to organ-specific autoimmune disease. Br J Dermatol 1969;81:83-8.
41. Howitz J, Schwartz M. Vitiligo, achlorhydria and pernicious anemia. Lancet 1971;l:1331-5.
42. Woolf son H, Finn OA, Mackie RM, et al. Serum antitumor antibodies and autoantibodies in vitiligo. Br J Dermatol 1973;88:127-37.
43. Brown AC, Olkowski Z, MacLaren J, et al. Alopecia areata and vitiligo associated with Down's syndrome. Arch Dermatol 1977;113:1269.
44. Grimes PE, Ghoneum M, Stockton T. T cell profile in vitiligo. J Am Acad Dermatol 1986;14:196-201.
45. Ortonne JP, Alario A. T and B lymphocytes in vitiligo. Arch Dermatol Res 1978;261:147-51.
46. Soubiran P, Benzaken S, Bellet C, et al. Vitiligo: Peripheral T-cell subset imbalance as defined by monoclonal antibodies. Br J Dermatol 1985;113(Suppl 28):124-7.
47. Durham-Pierre DC, Walters CS, Halder RM, et al. Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 1995; 33:26-30.
48. Cui J, Arita Y, Bystryn J-C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Derm 1993;100:812-5.
49. Yu H-S, Kao C-H, Yu C-L. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993;100:823-8.
50. Harning R, Cui J, Bystryn J-C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Derm 1991;97:1078-80.
51. Fishman P, Azizi E, Shoenfeld Y, et al. Vitiligo autoantibodies are effective against melanoma. Cancer 1993;72: 2365-9.
52. Gilhar A, Zelickson B, Ulman Y, et al. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995;105:683-6.
53. Naughton GK, Reggiardo MD, Bystryn J-C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-81.
54. Harm S-K, Chen DL, Bystryn J-C. Systemic steroids suppress anti-melanocyte antibodies in vitiligo. J Cutan Med Surg 1997;l:193-95.
55. Naughton GK, Mahaffey M, Bystryn J-C. Antibodies to surface antigens of pigmented cells in animals with vitiligo. Proc Soc Exp Biol Med 1986;181:423-6.
56. Cui J, Chen D, Misfeldt M, Swinfard R, et al. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995;8:60-3.
57. Austin LM, Boissy RE, Jacobson BS, et al. The detection of melanocyte autoantibodies in the Smyth chicken model for vitiligo. Clin Immunol and Immunother 1992;64:11220.
58. Harm SK, Park Y-K, Lee K-G, et al. Epidermal changes in active vitiligo. J Dermatol 1992;19:217-22.
59. AI Badri AMT, Todd PM, Gariochi JJ, et al. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993;170:149-55.
60. Nordlund JJ, Lerner AB. Vitiligo: It is important. Arch Dermatol 1982;118:5-8.
61. Le Poole 1C, van den Wijngaard RMJGJ, Westerhof W, et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996;148:1219-28.
62. Al Badri AMT, Foulis AK, Todd PM, et al. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 1993;169:203-6.
63. Abdel-Naser MB, Ludwig W-D, Gollnick H, et al. Nonsegmental vitiligo: Decrease of the CD45RA+ T-cell subset and evidence for peripheral T-cell activation. Int J Dermatol 1992;31:321-6.
64. Boissy RE, Fite KV, Smyth JR Jr. Progressive cytolytic changes during the development of delayed feather amelanosis and associated choroidal defects in DAM chicken line-A vitiligo model. Am J Pathol 1983;111:197212.
65. Boissy RE, Lamont SJ, Smyth JR Jr. Persistence of abnormal melanocytes in immunosuppressed chickens of the autoimmune DAM line. Cell Tissue Res 1984;235:663-8.
66. Cui J, Harning R, Henn M, et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992;98:162-5.
67. Cui J, Bystryn J-C. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995;131:314-8.
68. Cui J, Arita Y, Bystryn J-C. Characterization of vitiligo antigens. Pigment Cell Res 1995;8:53-9.
69. Song YH, Connor E, Li Y, et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1994;344:1049-52.
70. Baharav E, Merimsli O, Shoenfeld Y, et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996;105:84-8.
71. Xie Z, Bystryn J-C. Anti-tyrosinase antibodies in vitiligo. J Invest Derm 1996;106:938.
72. Houghton AN, Vijayasaradhi S, Bouchard B, et al. Recognition of autoantigens by patients with melanoma. In: Bystryn J-C, Ferrone S, Livingston P, editors. Specific immunotherapv of cancer with vaccines. New York: New York Academy of Sciences, 1993:59-68.
73. Harn I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein. J Exp Med 1995;182:1609-14.
74. Tobin DJ, Bystryn J-C. Different populations of melanocvtes are present in hair follicles and epidermis. Personal communication.
75. Heaney-Kieras J, Bystryn J-C. Identification and purification of a 75k dalton cell-surface human melanoma associated antigen. Cancer Res 1982:42:2310-9.
76. Thomson TM, Mattes MJ, Roux L, et al. Pigmentationassociated giycoprotein of human melanomas and melanocytes: Definition with a mouse monoclonal antibody. J Invest Dermatol 1985;85:169-74.
77. Merimsky O, Shoenfeld Y, Yecheskel G, et al. Vitiligo-and melanoma-associated hypopigmentation: A similar appearance but a different mechanism. Cancer Immunol Immunother 1994;38:411-6.
78. Arrunategui A, Arroyo C, Garcia L, et al. Melanocyte reservoir in vitiligo. Int J Dermatol 1994;33:484-7.
79. Cui J, Shen L, Wang G. Role of hair follicles in the repigmentation of vitiligo. J Invest IX'nruitol 1991;97: 410-6.
80. Bystryn J-C, Cui J. Vitiligo. In: Bonn CA, Sirnmovitch K A, Zanetti M, et al, editors. The molecular pathology of autoimmune diseases. Switzerland: Hardwood Academic, 1993:556-61.
81. Bystryn J-C, Xie Z. Hypomelanosis-neopinstic. in: Nordlund JJ, Boissy RE, Hearing V], King K A, Ortonne J-P, editors. The pigmentary system: Physiology and pathophysiology. New York: Oxford UniversiK Press, in press.
82. Bystryn J-C, Rigel D, Friedman RJ, et al Prognostic significance of hvpopigmentation in malignant melanoma. Arch Dermatol 1987;! 23:1053-5.
83. Hornung MO, Krementz ET. Specific tissue responses of chimpanzees following immunization against human melanoma. Surgery 1974;75:477-86.
84. Lacour JP, Caldani C, Thyss A, et al. Vniligo-iike depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma. Dermatology 1992;184:283-5.
85. Wolkenstein P, Revuz J, Guillaume 1C, et al. Autoimmune disorders and interleukin-2 therapy: A ^tep toward "unanswered questions." Arch Dermatol 1995;131:615b.
86. Richards JM, Gilewski TA, Ramming k, et ai Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 1992;69:427-9.
87. Wolkenstein P, Chosidow O, Guillaume I-C, et ai. Lesions vitiligoides au cours des melanomas metastases traites par i.nterleukine-2: 4 observations, Ann Dermatol Venereol 1992:119:907-9.
88. Oxenhandler RW, Adelstein EH, Haigh il"'., et al. Malignant melanoma in the Sinclair miniature v.vine. Am I Pathol 1979;96:707-20.
89. Brichard V, Van Pel A, Woelfel T. et .il. The lyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-.A2 meianomas. {Fxp Med 1993:17H:489-9